Multispecific Approach Could Improve I-O Side Effect Profile, Says Numab

Multispecific antibody therapeutic developer Numab – run by two former Esbatech executives – has come of age with a deal in the IO space that validates its technology. Could this mean bispecific programs have had their day?

Numab AG was known as the rabbit antibody company, but times have moved on. It still uses rabbits as a source of antibodies, but it can now humanize and stabilize the variable domain of these antibodies, and these antibody fragments can be used as building blocks for multispecific antibody therapies.

The promise of Numab's technology was recently recognized by Japan's Ono Pharmaceutical Co. Ltd. The two companies recently entered an agreement to develop a multispecific antibody candidate for one...

More from Business

More from Scrip